PTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to PTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update

PTC Therapeutics (PTCT) Tops Q1 EPS by 18c

May 8, 2017 7:31 AM EDT

PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($0.85), $0.18 better than the analyst estimate of ($1.03). Revenue for the quarter came in at $26.5 million versus the consensus estimate of $28.65 million.

"We are thrilled to bring EMFLAZA to Duchenne muscular dystrophy patients in the United States,\" said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "The acquisition of EMFLAZA supports our commitment to providing new treatment options for Duchenne patients. We plan to launch EMFLAZA in the coming weeks and are focused on providing access to all eligible patients. We are also pleased... More